Related Experiment Video

Updated: Feb 27, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

[MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2]

Yonghua Mi1, Miao He2, Beizhong Liu1

  • 1Department of Laboratory, Yongchuan Affiliated Hospital Chongqing Medical University, Chongqing 402160, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|June 24, 2017
PubMed
Abstract

Insights

MicroRNA-133b (miR-133b) inhibits lung cancer stem cell proliferation by targeting PKM2. Upregulating miR-133b enhances sensitivity to DDP chemotherapy, offering a potential therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNA-133b (miR-133b) is known to inhibit cancer cell growth and increase radiation sensitivity.
  • Reduced miR-133b expression is observed in lung cancer tissues and patient serum.
  • The precise mechanisms by which miR-133b affects lung cancer, particularly stem cells, remain unclear.

Purpose of the Study:

  • To investigate the impact of miR-133b on the proliferation of A549 lung cancer stem cells.
  • To assess the effect of miR-133b on drug sensitivity to DDP (cisplatin).
  • To explore the relationship between miR-133b and the PKM2 gene in lung cancer stem cells.

Main Methods:

  • Bioinformatic analysis using miRBase and miRNAMap to predict interactions between miR-133b and PKM2.
  • Isolation of CD133+/CD34+ lung cancer stem cells from A549 cells using immune magnetic separation.
  • Quantification of miR-133b mRNA via qRT-PCR, cell proliferation by CCK8 assay, and apoptosis by flow cytometry.
  • Western blot analysis to detect PKM2 protein expression.

Main Results:

  • PKM2 was identified as a potential direct target gene of miR-133b.
  • Overexpression of miR-133b significantly decreased lung cancer stem cell proliferation and lowered PKM2 protein levels.
  • Inhibition of miR-133b led to increased proliferation and PKM2 levels.
  • miR-133b overexpression enhanced apoptosis in cells treated with DDP and reduced PKM2 expression.

Conclusions:

  • miR-133b inhibits lung cancer stem cell growth and proliferation by downregulating PKM2.
  • Upregulation of miR-133b enhances the sensitivity of lung cancer stem cells to DDP chemotherapy.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K